At-large Member

Associate Professor, Group Leader and Associate Director (Research) at the Institute for Glycomics, Griffith University, Australia.

Kate completed a PhD in microbiology in 2004 from the University of Queensland (Brisbane, Australia) in the area of oxidative stress defenses of Neisseria gonorrhoeae and Neisseria meningitidis. She then spent 7 years at Novartis Vaccines (Siena, Italy) as a Postdoctoral Fellow and Project Leader, and was part of the team working on the serogroup B meningococcalvaccine, 4CMenB (Bexsero). She is now largely focused on gonococcal vaccine antigen discovery and development and is also leading a clinical trial to test the ability of 4CMenB to protect against N. gonorrhoeae.